Guardion’s Lumega-Z Formula Associated with Substantial Clinical Improvement in Patients Contrast Sensitivity Visual Function (CSF) vs AREDS 2

In a recent study presented at the Association for Research in Vision and Ophthalmology (ARVO) 2019 annual meeting, improvements in visual function (CSF) in the Lumega-Z Group were statistically significant and definitive. The AREDS 2 Group showed no statistical change.     San Diego, CA – May 9, 2019 – Guardion Health Sciences, Inc. (Nasdaq: […]

Guardion’s Lumega-Z Formula Associated with Improved Vision in Patients with Severe Glaucoma

In a recent study presented at the Association for Research in Vision and Ophthalmology (ARVO) 2019 annual meeting, treatment with Lumega-Z was associated with significant improvement in Visual Field function among patients with severe glaucoma   San Diego, CA – May 7, 2019 – Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”), an […]

Guardion Health Sciences, Inc. Receives Official Trademark Registrations in China

Guardion’s Lumega-Z product and MapcatSF device are key components of its two-pronged evidence-based protocol for the treatment of a depleted macular protective pigment, a known risk factor for age-related macular degeneration   San Diego, CA – May 01, 2019 – Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (Nasdaq: GHSI), an ocular health sciences and […]